DBV Technologies S.A.
DBVT
Health Care
2
exclusion reasons
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company whose core product development pipeline relies on animal testing. The company’s lead investigational therapy for food allergies, Viaskin, has been developed using animal models to establish preclinical safety and efficacy data, a standard requirement in the pharmaceutical industry. This business model inherently involves the commercial exploitation of animals for research purposes.
The company’s clinical trial documentation explicitly states adherence to principles requiring respect for the welfare of animals used in research, acknowledging this activity as fundamental to its operations. As a developer of biological products, DBV’s research and development process is contingent on animal testing to meet regulatory standards, placing animal exploitation at the center of its business model.
DBV Technologies S.A. is a clinical-stage biopharmaceutical company developing a novel food allergy immunotherapy platform called Viaskin™. The company's lead product candidate, Viaskin Peanut, is designed to treat peanut allergy through epicutaneous immunotherapy (EPIT). As disclosed in its 2023 Annual Report (Form 10-K), the regulatory pathway for such a biologic product requires demonstration of safety and efficacy "through analytical studies, animal studies, and a clinical trial or trials." This confirms animal testing is an integral, non-outsourceable component of DBV Technologies' core product development and regulatory compliance process.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.